| 2013 | Mihály Zs, Kormos M, Lánczky A, Dank M, Budczies J, Szász AM, Győrffy B: A meta-analysis of gene expression based biomarkers predicting outcome after tamoxifen treatment in breast cancer. In: Breast Cancer Res Treat, 2013, in press |
|---|
| 2013 | Maciejczyk A, Lacko A, Ekiert M, Jagoda E, Wysocka T, Matkowski R Halon A, Győrffy B, Lage H, Surowiak P: Elevated nuclear S100P expression is associated with poor survival in early breast cancer patients. In: Histology and Histopathology, 2013, 513-524 |
|---|
| 2013 | Magnani L, Stoeck A, Zhang X, Lánczky A, Mirabella AC, Wang TL, Győrffy B, Lupien M: Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer. In: Proc Natl Acad Sci U S A, 2013, 1490-1499 |
|---|
| 2013 | Pénzváltó Zs, Tegze B, Szász AM, Sztupinszki Zs, Likó I, Szendrői A, Schäfer R, Győrffy B: Identifying Resistance Mechanisms against five Tyrosine Kinase Inhibitors Targeting the ERBB/RAS Pathway in 45 Cancer Cell Lines. In: PLoS One, 2013, e59503 |
|---|
| 2013 | Malek A, Győrffy B, Catapano CV, Schäfer R: Selection of optimal combinations of target genes for therapeutic multi-gene silencing based on miRNA co-regulation. In: Cancer Gene Therapy, 2013, 326-329 |
|---|
| 2013 | Szász AM, Eklund AC, Li Q, Sztupinszki Z, Tőkés AM, Rowan A, Székely B, Kiss A, Szendrői M, Győrffy B, Szállási Z, Swanton C, Kulka J: The CIN4 chromosomal instability qPCR classifier defines tumour aneuploidy and stratifies outcome in grade 2 breast cancer. In: PLoS One, 2013, e56707 |
|---|
| 2012 | Mihály Z, Sztupinszki Z, Surowiak P, Győrffy B: A comprehensive overview of targeted therapy in metastatic renal cell carcinoma. In: Curr Cancer Drug Targets, 2012, 857-872 |
|---|
| 2012 | Budczies J, Klauschen F, Sinn BV, Győrffy B, Schmitt WD, Darb-Esfahani S, Denkert C.: Cutoff finder: a comprehensive and straightforward web application enabling rapid biomarker cutoff optimization. In: PLoS One, 2012, e51862 |
|---|
